N Engl J Med 2010 Jul 29
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Related Questions
New answer by Medical Oncologist at Washington University School of Medicine (August 8, 2018)
First and foremost, of course, confirmation that androgen deprivation (ie testosterone <50 ng/dl) has been achieved should be obtained. While uncommon, primary resistance t...